Abstract
Methods After IRB approval and informed consent, patients with pulmonary valve disease were prospectively scheduled for 1.5-T CMR before and after transcatehter valve implantation. We used a cine true-FISP sequence (TR/TE = 45/1.5 ms, thickness 7 mm) for evaluating the right ventricle (RV) function and a turbo-FLASH phase-velocity mapping sequence (41/3.2 ms, 5 mm, respectively; velocity encoding 250 ms) for pulmonary flow evaluation. Pressure gradient (ΔP) was estimated from peak flow velocity using Bernoulli's equation. McNemar and Wilcoxon tests were used.
Highlights
CMR can be used for a comprehensive noninvasive assessment of cardiac performance after pulmonary transcatheter valve implantation
From January 2008 to March 2009, we enrolled 12 patients, all of them studied within one week before valve implantation and 1 month after
All CMR examinations were diagnostic, with metallic artifacts limited to the Figure 1
Summary
CMR can be used for a comprehensive noninvasive assessment of cardiac performance after pulmonary transcatheter valve implantation. A non-invasive evaluation of the valve is foundamental in young pantients Purpose. To evaluate the diagnostic value of CMR before and after pulmonary transcatheter valve (Melody, Medtronic) implantation. A pulmonary regurgitant fraction was observed in 7/ 12 with a mean ΔP of 40 ± 11 mmHg; after valve implantation, no patients had regurgitant fraction (P = .016) and mean ΔP was 18 ± 12 mmHg (P = .003). End-diastolic volume index (EDVI), end-systolic volume index (ESVI), and ejection fraction (EF) of right ventricle (RV) before valve implantation were 71 ± 20 mL/m2, 34 ± 16 mL/m2, and 53 ± 9%, the same data after valve implantation being 64
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
